U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07876336) titled 'Prevalence of CYP2C19 Genetic Polymorphisms Among Egyptian Patients Receiving Clopidogrel Following PCI' on Oct. 09.
Brief Summary: Coronary artery disease occurs when the blood vessels supplying the heart become narrowed or blocked. Percutaneous coronary intervention (PCI) is a procedure used to restore blood flow to the heart, often by inserting a stent. After PCI, patients are commonly treated with dual antiplatelet therapy, which usually includes aspirin and a second medicine, such as clopidogrel, to reduce the risk of blood clots.
Clopidogrel must be converted by the body into its active form before it can work effectively. An...